Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHR A 1921

Next Previous
Drug Profile

SHR A 1921

Alternative Names: SHR-1921; SHR-A 1921

Latest Information Update: 04 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Suncadia Biopharmaceuticals
  • Developer Atridia; Beijing GoBroad Hospital; Suzhou Suncadia Biopharmaceuticals
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ovarian cancer
  • Phase II HER2 negative breast cancer; Salivary gland cancer; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 08 Apr 2026 Suzhou Suncadia Biopharmaceuticals withdraws a phase I/II trial prior to enrolment for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease) due to sponsors strategic adjustment (NCT06434103)
  • 09 Dec 2025 Efficacy and adverse events data from a phase II trial in Triple-negative-breast-cancer presented at the 48th Annual San Antonio Breast Cancer Symposium (SABCS-2025)
  • 17 Oct 2025 Pooled efficacy and adverse events data from a phase I trial in Triple-negative breast cancer presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top